Literature DB >> 16596660

Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid.

Alison Curnow1, Alexander J MacRobert, Stephen G Bown.   

Abstract

BACKGROUND AND OBJECTIVES: Enhancement of photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) has been demonstrated experimentally using light dose fractionation or CP94 iron chelation. This study extends this research. STUDY DESIGN/
MATERIALS AND METHODS: In normal rat colon, CP94 administration and light dose fractionation were independently and concurrently employed to enhance ALA-PDT. In colonic rat tumors, the most successful enhancement regimes were employed separately.
RESULTS: Independent use of light dose fractionation and iron chelation produced similar results in normal colon (2.4- and 2.9-fold more necrosis than controls, respectively). Using both techniques simultaneously produced fivefold enhancement. In the colonic tumors, light dose fractionation and iron chelation (using different parameters) produced two and five times the volume of necrosis, respectively.
CONCLUSIONS: Both techniques significantly enhanced ALA-PDT in the normal and neoplastic tissues investigated and produced similar levels of enhancement when comparable parameters were employed. Concurrent use of light dose fractionation and iron chelation in normal colon produced considerably more enhancement than either technique could achieve independently. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596660     DOI: 10.1002/lsm.20328

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  8 in total

Review 1.  Photodynamic therapy for focal ablation of the prostate.

Authors:  Nimalan Arumainayagam; C M Moore; Hashim U Ahmed; M Emberton
Journal:  World J Urol       Date:  2010-05-09       Impact factor: 4.226

Review 2.  Photodynamic therapy for prostate cancer--a review of current status and future promise.

Authors:  Caroline M Moore; Doug Pendse; Mark Emberton
Journal:  Nat Clin Pract Urol       Date:  2009-01

Review 3.  Photodynamic Therapy and the Biophysics of the Tumor Microenvironment.

Authors:  Aaron J Sorrin; Mustafa Kemal Ruhi; Nathaniel A Ferlic; Vida Karimnia; William J Polacheck; Jonathan P Celli; Huang-Chiao Huang; Imran Rizvi
Journal:  Photochem Photobiol       Date:  2020-03-05       Impact factor: 3.421

4.  Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial.

Authors:  Maximilien Vermandel; Clément Dupont; Fabienne Lecomte; Henri-Arthur Leroy; Constantin Tuleasca; Serge Mordon; Constantinos G Hadjipanayis; Nicolas Reyns
Journal:  J Neurooncol       Date:  2021-03-20       Impact factor: 4.130

5.  Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.

Authors:  Alison Curnow; Alexis Perry; Mark Wood
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-12-13       Impact factor: 3.631

6.  Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid.

Authors:  Izumi Kirino; Katsuhiko Fujita; Kei Sakanoue; Rin Sugita; Kento Yamagishi; Shinji Takeoka; Toshinori Fujie; Shinji Uemoto; Yuji Morimoto
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

7.  Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.

Authors:  Ana Luiza Ribeiro de Souza; Kayla Marra; Jason Gunn; Kimberley S Samkoe; Stephen Chad Kanick; Scott C Davis; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Br J Cancer       Date:  2016-08-30       Impact factor: 7.640

8.  An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.

Authors:  Lizette Anayo; Anette Magnussen; Alexis Perry; Mark Wood; Alison Curnow
Journal:  Lasers Surg Med       Date:  2018-03-31       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.